Monday, June 28, 2021 1:08:35 PM
Sufentanil is an opioid analgesic currently marketed for IV and epidural anesthesia and analgesia; however, its postoperative use has been limited due to its short duration of action when delivered intravenously.1
The pharmaceutical attributes of sufentanil, including lipid solubility and degree of non-ionization, result in rapid cell membrane penetration allowing entry into the central nervous system (CNS).2 In addition, its pharmacokinetic profile when delivered sublingually could potentially avoid the high peak plasma levels and short duration of action observed with IV administration.3 Sufentanil has been shown to be 5- to 10-fold more potent than fentanyl4. The following additional differences to other opioids have been observed:
No Active Metabolites: Active metabolites can increase the risk of delayed opioid side effects. Morphine, for example, has the active metabolite morphine-6-glucuronide (M6G) and M3G and hydromorphone has the active metabolite hydromorphone-6-glucuronide (H6G) and H3G, which can accumulate in renally impaired or elderly patients.5-7
Rapid Transmucosal Uptake: Sufentanil is highly lipophilic and is readily absorbed through mucosal tissues8 and distributed throughout the body. The short 6-minute brain:plasma equilibration half-life (t1/2ke0) of sufentanil demonstrates its ease of penetrating into the CNS.9
High Therapeutic Index: In animal studies, sufentanil has one of the highest therapeutic indexes (~27,000) of any commercially available opioid.10 The therapeutic index is the ratio of the lethal dose to the effective dose of a drug. These differences may potentially result in clinically relevant improvements for patients.
AcelRx's proprietary, noninvasive sublingual formulation technology efficiently delivers highly lipophilic drugs with consistent pharmacokinetic profiles. These sublingual dosage forms are designed to minimize the natural saliva response, thereby potentially reducing the amount of swallowed drug that results from typical oral transmucosal products. Drug absorbed from the gastrointestinal (GI) tract can potentially lead to more erratic and delayed timing to peak plasma levels compared to transmucosal absorbtion.10,11
Sufentanil Sublingual Mechanism of Action
Recent TLPH News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:11:29 PM
- Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:55:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:54:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:53:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:13 PM
- Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members • PR Newswire (US) • 03/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:06:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:01:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 01:58:02 AM
- Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024 • PR Newswire (US) • 02/26/2024 09:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:58:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/14/2024 05:15:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:44:54 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:42:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 02:40:32 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:00:48 AM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 02/13/2024 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/06/2024 09:44:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 11:03:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:22:41 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 10:21:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 10:12:16 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM